Glox Therapeutics Awarded Share of 3M Collaborative Discovery Programme Funding from Cystic Fibrosis Antimicrobial Resistance Syndicate

Glox Therapeutics has been awarded a portion of a 3 million fund from the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate to develop novel precision antibiotics. With up to 500,000 in funding, the company aims to tackle drug-resistant lung infections prevalent among cystic fibrosis patients, of which over 162,000 are estimated globally. Their innovative approach uses engineered bacteriocins to selectively target harmful bacteria like Pseudomonas aeruginosa while preserving the human microbiome, providing a potential new solution to a growing medical challenge.

Glox Therapeutics will utilize a share of the 3 million CDP fund to develop precision antibiotics to combat antimicrobial-resistant infections in Cystic Fibrosis patients.

Read at siliconvalleyjournals.com